Prolonged interval hypofractionated radiotherapy facilitates better antitumor immunity.

Autor:	Xiao J; Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer Sichuan Cancer Center, Sichuan Cancer Hospital&Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China; School of Medicine University of Electronic Science and Technology of China Chengdu, China., Shao S; Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer Sichuan Cancer Center, Sichuan Cancer Hospital&Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China; School of Medicine University of Electronic Science and Technology of China Chengdu, China., Deng Y; Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer Sichuan Cancer Center, Sichuan Cancer Hospital&Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China; School of Medicine University of Electronic Science and Technology of China Chengdu, China., Wang D; Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer Sichuan Cancer Center, Sichuan Cancer Hospital&Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Liu Y; Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer Sichuan Cancer Center, Sichuan Cancer Hospital&Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., He S; Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer Sichuan Cancer Center, Sichuan Cancer Hospital&Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Zhao Y; Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer Sichuan Cancer Center, Sichuan Cancer Hospital&Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China; School of Medicine University of Electronic Science and Technology of China Chengdu, China., Liao W; Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer Sichuan Cancer Center, Sichuan Cancer Hospital&Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China; School of Medicine University of Electronic Science and Technology of China Chengdu, China., Zhang J; Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer Sichuan Cancer Center, Sichuan Cancer Hospital&Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Yang M; Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer Sichuan Cancer Center, Sichuan Cancer Hospital&Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China; School of Medicine University of Electronic Science and Technology of China Chengdu, China., Zhang S; Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer Sichuan Cancer Center, Sichuan Cancer Hospital&Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China; School of Medicine University of Electronic Science and Technology of China Chengdu, China. Electronic address: zhangsc65@hotmail.com.
Jazyk:	angličtina
Zdroj:	Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2024 Dec 06; Vol. 203, pp. 110664. Date of Electronic Publication: 2024 Dec 06.
DOI:	10.1016/j.radonc.2024.110664
Abstrakt:	Purpose: To evaluate the impact of hypofractionated radiotherapy (Hypo-RT) with different interfraction intervals on tumor growth, immune response, and synergistic effects with anti-PD-1 immunotherapy. Methods: The mouse MC38 colon cancer model was utilized. Various radiation regimens were designed to investigate the effects of fraction interval and fraction size on tumor growth, immune mobilization, and combination effects with anti-PD-1 immunotherapy. Results: For a fixed-dose experiment, the 6 × 5 Gy for every other day (qod) regimen demonstrated an equivalent effect on tumor growth compared to the 6 × 5 Gy once daily (qd) regimen, while the 6 × 5 Gy for twice weekly (biw) regimen failed to inhibit tumor growth. Both qod and biw regimens induced an enhanced immune response, unlike the qd regimen. For a fixed biologically equivalent dose experiment, 6 × 5 Gy qod, 4 × 7 Gy biw, and 2 × 11 Gy once weekly (qw) regimens exhibited similar tumor suppression to the 12 × 3 Gy qd regimen. The long-interval Hypo-RT regimens significantly mobilized host immunity, whereas 12 × 3 Gy qd did not. The peripheral and intratumoral T cells increased as the fraction interval and size increased. All Hypo-RT regimens combined with anti-PD-1 immunotherapy demonstrated higher intratumoral CD8 + T cells and more effective tumor growth delay compared to the 12 × 3 Gy qd regime. Conclusions: The current study suggested that a prolonged inter-fraction interval with an increased fraction size in Hypo-RT may be a promising option to balance the therapeutic effect on tumor and immune activation. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024. Published by Elsevier B.V.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect